Connor Clark & Lunn Investment Management Ltd. cut its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 59.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,791 shares of the company's stock after selling 71,796 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.09% of EyePoint Pharmaceuticals worth $390,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Greenwich Wealth Management LLC increased its stake in EyePoint Pharmaceuticals by 8.3% during the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company's stock valued at $93,000 after purchasing an additional 900 shares during the last quarter. Arizona State Retirement System raised its stake in EyePoint Pharmaceuticals by 9.7% during the second quarter. Arizona State Retirement System now owns 13,251 shares of the company's stock worth $115,000 after acquiring an additional 1,171 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in EyePoint Pharmaceuticals by 68.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock worth $82,000 after acquiring an additional 4,172 shares during the period. Fiera Capital Corp lifted its holdings in EyePoint Pharmaceuticals by 0.9% in the second quarter. Fiera Capital Corp now owns 677,038 shares of the company's stock worth $5,890,000 after acquiring an additional 5,920 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in EyePoint Pharmaceuticals by 271.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company's stock valued at $95,000 after acquiring an additional 7,953 shares during the period. Institutional investors and hedge funds own 99.41% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. cut their target price on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 13th. Scotiabank initiated coverage on shares of EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $18.00 price objective on the stock. Chardan Capital upped their target price on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, November 8th. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a report on Saturday, September 21st. Finally, HC Wainwright decreased their price objective on EyePoint Pharmaceuticals from $30.00 to $22.00 and set a "buy" rating for the company in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, EyePoint Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $28.00.
Check Out Our Latest Analysis on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Trading Down 2.2 %
NASDAQ:EYPT traded down $0.20 during trading hours on Friday, hitting $8.85. 377,182 shares of the company traded hands, compared to its average volume of 863,411. The stock has a market capitalization of $604.01 million, a price-to-earnings ratio of -4.43 and a beta of 1.50. The firm has a 50-day moving average of $9.78 and a 200 day moving average of $9.43. EyePoint Pharmaceuticals, Inc. has a twelve month low of $5.98 and a twelve month high of $30.99.
About EyePoint Pharmaceuticals
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Featured Stories
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
